Clinical trials: Systolic Blood Pressure
Cognitively Normal Older Adults, Hypertension
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
The purpose of this study is to determine if intensive lowering of systolic blood pressure (SBP), using FDA approved medications (antihypertensive), reduces Alzheimer's Disease pathology (i.e., excessive brain amyloid and tau…
- Conditions
- Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Dementia
- Trial name
- IPAT (NCT05331144)
- Testing
- Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine), PCP
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Rong Zhang
Hypertension, Hypertension, Systolic
Treatment of Hypertension During Sleep
On the basis of new evidence on the relationship between achieved office blood pressure (BP) measurements (OBPM) and the risk of cardiovascular disease (CVD) morbidity and mortality documented in the SPRINT trial, the recent 2017…
- Trial name
- THADEUS (NCT03457168)
- Testing
- Treatment of elevated asleep SBP mean
- Where
- 9 sites in Spain
- Volunteers
- 5,320 people
- Sponsor
- University of Vigo
Treatment Adherence and Compliance
A Factorial Approach to Improve Treatment Adherence and Systolic Blood Pressure
In Pakistan, poor medication adherence is a key operational factor in the prevalence of uncontrolled hypertension. Mobile phone treatments based on technology are at the forefront and are a reasonably low-cost strategy for…
- Trial name
- NCT05106790
- Testing
- Educational support with peer counseling, mHealth intervention, mHealth intervention and Educational support with peer counseling
- Where
- 6 sites in Pakistan
- Volunteers
- 1,440 people
- Sponsor
- Universiti Putra Malaysia
Arterial Hypertension, Ischemic Heart Disease
Selective Vagus Nerve Stimulation in Human
The investigators would like to explore possibilities of selective vagus nerve stimulation in human subjects to control heart rate and arterial blood pressure.
- Trial name
- VNS (NCT00983632)
- Testing
- Selective vagus nerve stimulation
- Where
- Slovenia
- Volunteers
- 4 people
- Sponsor
- University Medical Centre Ljubljana
Hypoxia
Clinical Validation of Vital-PICASO for Predicting Hypoxia Within 24 Hours in General Ward Inpatients
The purpose of this retrospective study is to evaluate the clinical performance of Vital-PICASO, an artificial intelligence-based biological signal analysis software designed to predict the risk of hypoxia within 24 hours using…
- Trial name
- NCT07742813
- Where
- South Korea
- Volunteers
- 2,250 people
- Sponsor
- Huinno AIM
Cirrhosis, Hepatic Encephalopathy
Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis
The study aims to compare the potential benefit of allopurinol versus atorvastatin in reducing the risk of developing cirrhosis-related complications, delaying the onset of hepatocellular carcinoma, and improving survival.
- Conditions
- Cirrhosis, Hepatic Encephalopathy, Ascites, Varices
- Trial name
- NCT05511766
- Testing
- Allopurinol 300 MG, Atorvastatin 20mg
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Tanta University
Hypertension, Hypertrophy, Left Ventricular
The SILVER Study: Systolic Hypertension Interaction With Left Ventricular Remodeling
The purpose of this study is to evaluate the safety and efficacy of ALT-711 in the treatment of isolated systolic hypertension in a formal study in patients with left ventricular hypertrophy.
- Trial name
- NCT00045994
- Testing
- ALT-711
- Volunteers
- 180 people
- Sponsor
- Synvista Therapeutics, Inc
Nontraumatic Intracerebral Hemorrhage, Multiple Localized
Clevidipine (Cleviprex®) Compared With Urapidil (Ebrantil®)
Intracerebral hemorrhage (ICH) is responsible for 10-15% of primary strokes. ICH is a dynamic process with three phases: initial hemorrhage, followed by hematoma expansion and perihematoma edema formation.
- Trial name
- Clevidipine (NCT03300479)
- Testing
- Clevidipine, Urapidil
- Where
- Switzerland
- Sponsor
- University of Zurich
Blood Pressure, Cardiovascular Diseases
SRMA of the Effect of Soy Protein on Blood Pressure
Hypertension is one of the leading risk factors for death and significantly increases the risk for cardiovascular (CVD), brain and kidney diseases.
- Trial name
- NCT05638061
- Testing
- Soy protein
- Where
- Canada
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Blood Pressure, High, Cardiovascular Risk Factor
Efficacy of a Brief Intervention on Reduction of Systolic Blood Pressure
This study examines the efficacy of individualized counseling letters to reduce systolic blood pressure level of ≥ 130 mmHg in individuals aged between 40 and 65 years.
- Trial name
- NCT03077373
- Testing
- Counseling letter
- Where
- Germany
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
Moderate to Severe Hypertension
Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension
This study will compare the blood pressure (BP) lowering effect of the combination of aliskiren/amlodipine 300/10 mg versus amlodipine 10 mg monotherapy in patients with moderate to severe hypertension by testing the hypothesis…
- Trial name
- NCT00841672
- Testing
- Aliskiren/amlodipine 300/10 mg tablet, Amlodipine 10 mg capsule
- Where
- 6 sites in Germany, Philippines and 4 more
- Volunteers
- 485 people
- Sponsor
- Novartis
Hypertension
Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus
The purpose of the study was to evaluate the blood pressure (BP)-lowering efficacy of the combination of aliskiren and valsartan, as initial therapy, compared to valsartan monotherapy in Type II Diabetic patients with Stage II…
- Trial name
- ViVID (NCT00927394)
- Testing
- Aliskiren, Valsartan
- Where
- 4 sites in United States
- Volunteers
- 1,143 people
- Sponsor
- Novartis
Type 1 Diabetes
Liraglutide in the Treatment of Type 1 Diabetes Mellitus
Hypothesis 1: Treatment with Liraglutide in patients with type 1 diabetes decreases fasting, postprandial and the overall mean glucose concentrations.
- Trial name
- NCT01722266
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University at Buffalo
Hypertension
Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension
The purpose of the study is to compare the combination of aliskiren, amlodipine and Hydrochlorothiazide (HCTZ) versus the combination of aliskiren and amlodipine as therapy in minority Stage 2 hypertensive patients.
- Trial name
- ASCENT (NCT00942994)
- Testing
- Aliskiren/Amlodipine, Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)
- Where
- 5 sites in United States
- Volunteers
- 412 people
- Sponsor
- Novartis
Hypertension
Reduction Of Dietary Salt Intake To Control Systolic Blood Pressure In Hypertensive Older Patients
REPRESS is an open label, pragmatic, multicenter, randomized controlled phase III trial with blinded endpoint with 1:1 (intervention to control arm) allocation ratio.
- Trial name
- REPRESS (NCT05976477)
- Testing
- educational intervention
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
Hypertension
Trial to Address Food Insecurity in Patients With Hypertension (SMART-FI)
In the US, 47% of adults have hypertension (HTN), and HTN accounts for more cardiovascular disease (CVD) deaths than any other CVD risk factor.
- Trial name
- SMART-FI (NCT05800145)
- Testing
- Resource information Supplemental Nutrition Assistance Program (SNAP), community health worker (CHW), medically tailored meals
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Wake Forest University Health Sciences
Otherwise Healthy Individuals With Systolic Blood Pressure (SBP) From 110 to 139 mmHg and Low-density Lipoprotein Cholesterol (LDL-C) ≥ 100 mg/dL
A Study to Evaluate COR-2003 as Monotherapy and Co-Administered With COR-1004 in Adult Volunteers
This clinical trial has two parts. In Part A, the goal is to learn about the safety and tolerability of COR-2003 when it is given alone.
- Trial name
- NCT07858019
- Testing
- COR-2003, COR-1004 + COR-2003
- Where
- 2 sites in Australia, New Zealand
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Corsera Health
Chronic Kidney Diseases, Hypertension
Remote Ischaemic Conditioning on Blood Pressure Control in Chronic Kidney Disease Patients
Chronic kidney disease (CKD) is one of the leading causes of death and disability in Singapore and worldwide. Hypertension is commonly inadequately controlled in patients with CKD and this is associated with CKD progression and…
- Conditions
- Chronic Kidney Diseases, Hypertension, Cardiovascular Diseases
- Trial name
- ERIC-BP-CKD (NCT03236350)
- Testing
- Active autoRIC® (CRIC Treatment)
- Where
- Singapore
- Volunteers
- 85 people
- Sponsor
- Singapore General Hospital
Major Adverse Cardiac-cerebral-kidney Event
MACE and First Operating Room Systolic Blood Pressure in Patients Undergoing Non-cardiac Surgery Implications for the Hypertension Threshold
To find the threshold of First operating room SBP above which MACE risk increases.
- Trial name
- NCT03185598
- Volunteers
- 90,342 people
- Sponsor
- Peking University First Hospital
Hypertension
Aliskiren Study of Safety and Efficacy in Senior Hypertensives
This study is designed to compare the blood pressure lowering efficacy of aliskiren, a combination of aliskiren plus amlodipine, and ramipril in elderly patients with mild to moderate hypertension.
- Trial name
- ASSESS (NCT01922141)
- Testing
- Aliskiren, Amlodipine, Ramipril
- Sponsor
- Novartis Pharmaceuticals